[Oncotargets and Therapy] Some data support use of immunotherapy for breast cancer; however, as a monotherapy, only a small percentage of patients will benefit from the treatment. This review discusses the current status of efforts to improve immunotherapy through combinations with other therapies.
Investigators suggest more personalized interventions may be needed to improve adherence rates among women with breast cancer receiving AI treatments.
Abemaciclib plus trastuzumab and fulvestrant significantly prolonged PFS compared with abemaciclib-trastuzumab or chemotherapy among previously treated women with advanced HR+/HER2+ breast cancer.
Women participating in mammography screening also had decrease in rate of advanced breast cancer.
This study focused on a cohort of nonelderly Medicaid beneficiaries with stage IV breast or colorectal cancer who resided in New Jersey.
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
Talazoparib failed to show an overall survival benefit for HER2-negative advanced breast cancer patients with a germline BRCA1/2 mutation.
Trodelvy is the first antibody-drug conjugate to get FDA approval for this indication.
[Breast Cancer: Targets and Therapy] A review of the data on this newer peptide vaccine being explored as potential vaccine therapy for HER2-positive and triple negative breast cancers.
Payer adoption of utilization management increased the uptake of guideline-recommended hypofractionated radiotherapy for eligible patients with early-stage breast cancer.
